References
- Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
- Stahl SM. The last diagnostic and statistical manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses. CNS Spectr. 2013;18:65–68.
- Hughes MM, Connor TJ, Harkin A. Stress-related immune markers in depression: implications for treatment. Int J Neuropsychopharmacol. 2016;pii:pyw001. doi:10.1093/ijnp/pyw001.
- Blier P. Neurotransmitter targeting in the treatment of depression. J Clin Psychiatry. 2013;74(Suppl 2):19–24.
- Zohar J, Stahl S, Möller HJ, et al. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol. 2015;25:2318–2325.
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–1917.
- Trivedy MH. Evaluating and monitoring treatment response in depression using measurement-based assessment and rating scales. J Clin Psychiatry. 2013;74:e14.
- Hassan AK, Farmer KC, Brahm NC, et al. Evaluating antidepressant treatment prior to adding second-line therapies among patients with treatment-resistant depression. Int J Clin Pharm. 2016;38:429–437.
- Silhan P, Urinovska R, Hyza M. Antidepressive drug monitoring in clinical practice –pros and cons [in Czech]. Psychiatrie. 2013;17(Suppl 1):35.
- Olfson M, Marcus SC, Tedeschi M, et al. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163:101–108.
- Bauer M, Severus E, Köhler S, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14:334–385.
- Stahl SM. Classifying psychotropic drugs by mode of action and not by target disorder. CNS Spectr. 2013;18:113–117.
- Ghanbari R, El Mansari M, Blier P. Electrophysiological impact of trazodone on the dopamine and norepinephrine systems in the rat brain. Eur Neuropsychopharmacol. 2012;22:518–526.
- Schosser A, Serretti A, Souery D, et al. European Group for the study of resistant depression (GSRD)–where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol. 2012;22:453–468.
- Hall-Flavin DK, Winner JG, Allen JD, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013;23:535–548.